Studies whether a food toxin may raise the risk of inflammatory bowel disease
Observes how a food toxin, deoxynivalenol, is processed in adults with inflammatory bowel disease.
Key facts
- Who runs it
- University Hospital, Lille
- Where
- Lille, FranceSee the site
- Trial code
- Registry title
- Study of an Environmental Risk Factor in Crohn's Disease
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 27 Sept 2021
- Planned end
- Jul 2026
- Type of study
- Observational, 2 groups
- Record updated
- 26 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Crohn's disease of the ileum and colon who need surgery. It also looks for adults who need bowel surgery for another reason, such as cancer, a polyp or a diverticulum.
- Age
- 25 to 60 years
- Sex
- Women and men can join.
- Disease stage
- Group 1: ileocolic Crohn's disease needing surgery. Group 2: needs ileal and/or colonic surgery for a reason other than Crohn's disease or ulcerative colitis.
- Earlier treatment
- No antibiotic or probiotic treatment in the 6 weeks before joining. No topical treatment (suppositories or enema of 5ASA or corticosteroids) in the 6 weeks before joining.
Main reasons for not taking part
- Vegetarian or vegan diet
- Celiac disease or gluten sensitivity
- Eating disorder, obesity or anorexia, or a particular diet or eating behavior
- Previous intestinal resection surgery
- Antibiotic, probiotic or topical treatment in the 6 weeks before joining
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Group 1: patients with ileocolic Crohn's disease requiring surgery
- Group 2: Patients requiring ileal and / or colonic surgery for a reason other than Crohn's disease or ulcerative colitis (for example, cancer, polyp or diverticulum)
Who cannot take part
- Surgical history: patient having undergone intestinal resection
- Current treatments: patient receiving antibiotic or probiotic treatment within 6 weeks prior to inclusion / patient having taken topical treatment (suppositories or enema of 5ASA or corticosteroids) within 6 weeks prior to inclusion
- Vegetarian or vegan patients, celiac disease, gluten sensitivity, eating disorders, people with a particular diet or eating behavior or suffering from obesity or anorexia
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 60 years old?
Where in France
- Lille University HospitalLille, FranceContact: Cécile VignalTaking people
About the trial
What the trial wants to find out
Inflammatory bowel disease (IBD) are lifelong chronic diseases affecting the gastrointestinal tract. The precise etiology and the different actors participating to the pathophysiological process leading to the disease development are still not well understood. A complex interaction between genetics, gut microbiota and environmental factors is thought to trigger the inappropriate mucosal immune response observed in IBD patients. We hypothesize that DON might be an environmental risk factor for IBD.The focus on the human relevance of the gut effects of DON by studying its exposure, metabolism and adverse effects in health and disease focusing on IBD patients
The 2 groups in the trial
- Crohn's disease patients
- Non IBD patients
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- dEoxyniValenol as Risk Factor for Inflammatory Bowel Diseases: Human detoxifiCaTion and Impact On intestiNal Microbiota and Homeostasis
- Plain-language title
- Studies whether a food toxin may raise the risk of inflammatory bowel diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT04960826, who can take part
- Record updated
- 26 December 2025